Knight Therapeutics to Acquire Grupo Biotoscana, Establishing a Latin American Growth Platform
Transformational acquisition establishes Knight as a premiere pan-American (ex-US) specialty pharma company Executes on Knight’s strategy to build a Rest of World specialty pharmaceutical company and become the partner of choice for top pharmaceutical companies for pan-American (ex-US) in-licensing opportunities Strong regional infrastructure and management team with a unique footprint across 10 countries in Latin […]
Knight Therapeutics Reports Second Quarter 2019 Results
MONTREAL, Aug. 08, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2019. All dollar amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q2 2019 Highlights Financials Revenues were $3,204, […]
Knight Therapeutics and pan-Canadian Pharmaceutical Alliance (pCPA) Reach Agreement for PROBUPHINE® for Opioid Dependence
AB, SK and NIHB are the first public drug plans to fund PROBUPHINE® recognizing benefits of new treatment option PROBUPHINE® is the first and only buprenorphine implant approved in Canada for the long-term maintenance management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counseling […]
Knight Announces Early Warning Filing Regarding Disposition of Shares of Crescita
MONTREAL, Aug. 06, 2019 — This press release is being disseminated by Knight Therapeutics Inc. (“Knight”) (TSX:GUD), a specialty pharmaceutical company, as required by National Instrument 62-103 – The Early Warning System and Related Take Over Bid and Insider Reporting Issues regarding the disposition of securities of Crescita Therapeutics Inc. (“Crescita”). Since July 15, 2019, […]
Notice of Knight Therapeutics’ Second Quarter 2019 Results Conference Call
MONTREAL, Aug. 01, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its second quarter 2019 financial results on Thursday, August 8, 2019 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in […]
Knight Therapeutics Announces Health Canada Has Approved NERLYNX ® for Early-Stage Breast Cancer
MONTREAL, July 16, 2019 — Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) for the extended adjuvant treatment of women with early-stage hormone receptor positive, HER2-overexpressed/amplified breast cancer within one year after completion of trastuzumab-based adjuvant therapy1. Knight has the exclusive right to […]
Knight Announces Normal Course Issuer Bid
MONTREAL, July 08, 2019 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company “), a leading Canadian specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the “TSX”) of the Company’s Notice of Intention to Make a Normal Course Issuer Bid (“NCIB”). Pursuant to the NCIB, the Company proposes to purchase, from time […]
Knight Announces Filing of New Drug Submission for Ibsrela™ in Canada
MONTREAL, June 26, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company, announced today that Knight’s New Drug Submission (NDS) for Ibsrela™ (tenapanor) has been accepted for review by Health Canada for the treatment of irritable bowel syndrome with constipation (IBS-C). Knight and Ardelyx Inc. (NASDAQ: ARDX) entered into a license agreement […]
Knight has less skin in Medimetriks through full loan repayment
MONTREAL, June 18, 2019 — Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Medimetriks Pharmaceuticals Inc. (“Medimetriks”) has prepaid the remaining US$750 thousand balance of Knight’s US$23 million secured strategic loan issued in 2016. Knight has generated over US$8.7 million from interest and fees from the strategic loan since […]
Knight to Present at the Raymond James Life Sciences and MedTech Conference in New York City
MONTREAL, June 11, 2019 — Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, Chief Executive Officer, is scheduled to present at the Raymond James Life Sciences and MedTech Conference on Tuesday, June 18, 2019 at 9:45 AM ET at the Lotte New York Palace hotel in […]
